Rational Design of Coumarin Derivatives as Antituberculosis Agents

References

• World Health Organization . WHO Global Tuberculosis Report 2017 (2017). www.who.int/tb/publications/global_report/gtbr2017_main_text.pdf .
   Google Scholar
• Pieters J . Mycobacterium tuberculosis and the macrophage: maintaining a balance. Cell Host Microbe3 (6), 399 – 407 (2008).
   PubMed Web of Science ®Google Scholar
• O'brien RJ . Drug-resistant tuberculosis: etiology, management and prevention. Semin. Respir. Infect.9 (2), 104 – 112 (1994).
   PubMedGoogle Scholar
• PA-824. Tuberculosis88 (2), 134 – 136 (2008).
   PubMedGoogle Scholar
• OPC-67683. Tuberculosis88 (2), 132 – 133 (2008).
   PubMedGoogle Scholar
• Ang CW Jarrad AM Cooper MA Blaskovich MaT . Nitroimidazoles: molecular fireworks that combat a broad spectrum of infectious diseases. J. Med. Chem.60 (18), 7636 – 7657 (2017).
   PubMed Web of Science ®Google Scholar
• Walsh JS Miwa GT . Bioactivation of drugs: risk and drug design. Annu. Rev. Pharmacol. Toxicol.51 (1), 145 – 167 (2011).
   PubMedGoogle Scholar
• Gurumurthy M Rao M Mukherjee T et al. A novel F420-dependent anti-oxidant mechanism protects Mycobacterium tuberculosis against oxidative stress and bactericidal agents. Mol. Microbiol.87 (4), 744 – 755 (2013).
   PubMed Web of Science ®Google Scholar
• Singh R Manjunatha U Boshoff HIM et al. PA-824 kills nonreplicating mycobacterium tuberculosis by intracellular NO release. Science322 (5906), 1392 (2008).
   PubMed Web of Science ®Google Scholar
• Graham DE . A new role for coenzyme F420 in aflatoxin reduction by soil mycobacteria. Mol. Microbiol.78 (3), 533 – 536 (2010).
   PubMed Web of Science ®Google Scholar
• Taylor MC Jackson CJ Tattersall DB et al. Identification and characterization of two families of F420H2-dependent reductases from Mycobacteria that catalyse aflatoxin degradation. Mol. Microbiol.78 (3), 561 – 575 (2010).
   PubMed Web of Science ®Google Scholar
• Gurumurthy M Mukherjee T Dowd CS et al. Substrate specificity of the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazoles. FEBS J.279 (1), 113 – 125 (2012).
   PubMed Web of Science ®Google Scholar
• Romualdo B Cecilia B . Structural alerts of mutagens and carcinogens. Curr. Comput. Aided Drug Des.2 (2), 169 – 176 (2006).
   Web of Science ®Google Scholar
• Xin-Mei P Guri LVD Cheng-He Z . Current developments of coumarin compounds in medicinal chemistry. Curr. Pharmaceut. Des.19 (21), 3884 – 3930 (2013).
   PubMed Web of Science ®Google Scholar
• Row EC Brown SA Stachulski AV Lennard MS . Design, synthesis and evaluation of furanocoumarin monomers as inhibitors of CYP3A4. Org. Biomol. Chem.4 (8), 1604 – 1610 (2006).
   PubMed Web of Science ®Google Scholar
• Maresca A Temperini C Pochet L Masereel B Scozzafava A Supuran CT . Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J. Med. Chem.53 (1), 335 – 344 (2010).
   PubMed Web of Science ®Google Scholar
• Sánchez-Recillas A Navarrete-Vázquez G Hidalgo-Figueroa S Rios MY Ibarra-Barajas M Estrada-Soto S . Semisynthesis, ex vivo evaluation, and SAR studies of coumarin derivatives as potential antiasthmatic drugs. Eur. J. Med. Chem.77, 400 – 408 (2014).
   PubMed Web of Science ®Google Scholar
• Huang W-J Wang Y-C Chao S-W et al. Synthesis and biological evaluation of ortho-Aryl N-hydroxycinnamides as potent histone deacetylase (HDAC) 8 Isoform-selective inhibitors. ChemMedChem7 (10), 1815 – 1824 (2012).
   PubMed Web of Science ®Google Scholar
• Joubert J Foka GB Repsold BP Oliver DW Kapp E Malan SF . Synthesis and evaluation of 7-substituted coumarin derivatives as multimodal monoamine oxidase-B and cholinesterase inhibitors for the treatment of Alzheimer's disease. Eur. J. Med. Chem.125, 853 – 864 (2017).
   PubMed Web of Science ®Google Scholar
• Vianna DR Ruschel L Dietrich F et al. 4-Methylcoumarins with cytotoxic activity against T24 and RT4 human bladder cancer cell lines. MedChemComm6 (5), 905 – 911 (2015).
   Web of Science ®Google Scholar
• Jiang Y Xu H Liu L He R Song X Li N . Synthesis and anti-cancer activities of aryl benzyl ethers with fluoro substituents. Lett. Drug Des. Discov.11 (6), 736 – 741 (2014).
   Web of Science ®Google Scholar
• Singh U Akhtar S Mishra A Sarkar D . A novel screening method based on menadione mediated rapid reduction of tetrazolium salt for testing of anti-mycobacterial agents. J. Microbiol. Methods84 (2), 202 – 207 (2011).
   PubMed Web of Science ®Google Scholar
• Khan A Sarkar D . A simple whole cell based high throughput screening protocol using Mycobacterium bovis BCG for inhibitors against dormant and active tubercle bacilli. J. Microbiol. Methods73 (1), 62 – 68 (2008).
   PubMed Web of Science ®Google Scholar
• Sarkar S Sarkar D . Potential use of nitrate reductase as a biomarker for the identification of active and dormant inhibitors of Mycobacterium tuberculosis in a THP1 infection Model. J. Biomol. Screen.17 (7), 966 – 973 (2012).
   PubMedGoogle Scholar
• Portaels JCP . Simple procedure for drug susceptibility testing of Mycobacterium tuberculosis using a commercial colorimetic assay. Eur. J. Clin. Microbiol. Infect. Dis.18 (5), 380 – 383 (1999).
   PubMed Web of Science ®Google Scholar
• Joanna B Pauline L Linda R Ruth M Ken D . Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol. Microbiol.43 (3), 717 – 731 (2002).
   PubMed Web of Science ®Google Scholar
• Mosmann T . Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods65 (1), 55 – 63 (1983).
   PubMed Web of Science ®Google Scholar
• Ciapetti G Cenni E Pratelli L Pizzoferrato A . In vitro evaluation of cell/biomaterial interaction by MTT assay. Biomaterials14 (5), 359 – 364 (1993).
   PubMed Web of Science ®Google Scholar
• Thompson AM Blaser A Anderson RF et al. Synthesis, reduction potentials, and antitubercular activity of ring A/B analogues of the bioreductive drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). J. Med. Chem.52 (3), 637 – 645 (2009).
   PubMed Web of Science ®Google Scholar
• Nguta JM Appiah-Opong R Nyarko AK Yeboah-Manu D Addo PGA . Current perspectives in drug discovery against tuberculosis from natural products. Int. J. Mycobacteriol.4 (3), 165 – 183 (2015).
   PubMed Web of Science ®Google Scholar